The Oncology Institute (The Oncology Institute) Cash-to-Debt : 0.55 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is The Oncology Institute Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. The Oncology Institute's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.55.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, The Oncology Institute couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for The Oncology Institute's Cash-to-Debt or its related term are showing as below:

TOI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.34 Med: 0.75 Max: No Debt
Current: 0.55

During the past 6 years, The Oncology Institute's highest Cash to Debt Ratio was No Debt. The lowest was 0.34. And the median was 0.75.

TOI's Cash-to-Debt is ranked worse than
52.35% of 659 companies
in the Healthcare Providers & Services industry
Industry Median: 0.66 vs TOI: 0.55

The Oncology Institute Cash-to-Debt Historical Data

The historical data trend for The Oncology Institute's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

The Oncology Institute Cash-to-Debt Chart

The Oncology Institute Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

0.50

624.59

0.68

0.69

The Oncology Institute Quarterly Data
	Sep18	Dec18	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial														0.50	0.34	0.75	0.69	0.55

Competitive Comparison of The Oncology Institute's Cash-to-Debt

For the Medical Care Facilities subindustry, The Oncology Institute's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Oncology Institute's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's Cash-to-Debt falls into.

The Oncology Institute Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

The Oncology Institute's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	82.855	/	(6.363	+	113.312)
	=	0.69

The Oncology Institute's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	65.832	/	(6.39	+	113.445)
	=	0.55

The Oncology Institute (NAS:TOI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

The Oncology Institute Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of The Oncology Institute's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

The Oncology Institute (The Oncology Institute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Oncology Institute Inc (NAS:TOI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703

Website

https://www.theoncologyinstitute.com

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.

Executives

Havencrest Healthcare Partners, L.p.	10 percent owner	5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039
Mihir Shah	officer: Chief Financial Officer, other: Principal Financial Officer	C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Brad Hively	director, officer: Chief Executive Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Jeremy Castle	officer: Chief Operating Officer	1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richard A Barasch	director, officer: Executive Chairman	C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573
Matthew P Miller	officer: Chief Operating Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Daniel Virnich	officer: Chief Operating Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Yale Podnos	officer: Chief Medical Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Diona Simoneit	officer: Chief Accounting Officer, other: Principal Accounting Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mohit Kaushal	director	44 SOUTH BROADWAY, WHITE PLAINS NY 10601
Gabriel Ling	director	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mark L Pacala	director	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richy Agajanian	10 percent owner	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Maeve O'meara	director	C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105
Toi Hc I, Llc	10 percent owner	2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201